SecBot SecBot
8-K ·Filed May 14, 2026

CRVS

Corvus Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001171843-26-003397
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The Phase 1 data shows best-in-class potential for soquelitinib in atopic dermatitis with durable drug-free remissions, a key differentiator from approved systemic therapies. The Phase 2 SIERRA1 trial enrollment and Angel Pharma's China trial results (late 2026) are the next catalysts. Monitor for partnership or licensing interest given the differentiated profile.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.66
T+0 close · May 14, 2026 · via day close
Latest settled
+0.62%
T+60 · $13.74
Vs SPY
−2.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $13.66entry
  2. T+1 · 6mo ago −9.85%α −8.62% · $12.31
  3. T+5 · 6mo ago −4.21%α −3.49% · $13.08
  4. T+20 · 5mo ago −12.63%α −11.77% · $11.93
  5. T+60 · 3mo ago +0.62%α −2.97% · $13.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corvus Pharmaceuticals presented final Phase 1 data for soquelitinib in atopic dermatitis at the SID Annual Meeting, showing 75% EASI 75 achievement in the 8-week cohort and durable drug-free remissions with no rebound. The biomarker data supports the novel ITK inhibition mechanism, including persistent Treg induction and JAK-STAT pathway modulation. The company is enrolling a Phase 2 SIERRA1 trial (~200 patients) and its partner Angel Pharmaceuticals is enrolling a Phase 1b/2 trial in China.

Key Facts

  • Phase 1 trial enrolled 72 patients with moderate-to-severe atopic dermatitis; 35% had prior systemic therapy
  • Cohort 4 (200 mg BID, 8 weeks): 75% achieved EASI 75, 25% achieved EASI 90, 33% achieved IGA 0/1
  • Cohort 3 (200 mg BID, 4 weeks): 50% achieved EASI 75, 8% achieved EASI 90, 25% achieved IGA 0/1
  • No disease rebound observed during drug-free follow-up (30-90 days); no rescue medications required
  • Adverse events occurred in 41.7% of soquelitinib and 41.7% of placebo patients; all Grade 1-2, no dose modifications
  • Biomarker data shows dose-dependent reduction in Th2 cells, persistent Treg increase, and JAK-STAT pathway inhibition
  • Phase 2 SIERRA1 trial enrolling ~200 patients with 12-week treatment and 90-day follow-up
  • Angel Pharmaceuticals enrolling Phase 1b/2 trial in China; initial results anticipated late 2026

Financial Impact

No financial data in filing; clinical-stage biotech with no approved products or revenue

Risk Factors

  • Phase 1 data is small (72 patients) and may not replicate in larger Phase 2/3 trials
  • Competition from approved JAK inhibitors and biologics with established safety profiles
  • No revenue or approved products; dependent on capital markets for funding
  • Regulatory path uncertain; FDA may require additional trials before approval

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-003397
Exhibit: exh_991.htm0001171843-26-003397
Document: 0001171843-26-003397-index-headers.html0001171843-26-003397
Document: 0001171843-26-003397-index.html0001171843-26-003397
Document: 0001171843-26-003397.txt0001171843-26-003397

Track record

15 reports on CRVS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
  4. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
  6. Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
  7. Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
  8. Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
  10. May 14, 202626w ago 8-K Bullish 7/10 Viewing Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026